July 23, 2020 – Abbott (Abbott, IL) received approval from the U.S. Food and Drug Administration (FDA) for the use of the company’s Patient Controller app on compatible personal Apple smartphone devices. At Abbott, this approval allows patients living with neurological conditions, including chronic pain or movement disorders, the ability to manage therapy directly from their personal smartphone.
The company says that, with this app approval, the need to carry a separate patient programmer device is eliminated, streamlining the patient’s experience and seamlessly integrating therapy management into their life.
The Patient Controller app will be integrated into Abbott’s broader NeuroSphere Digital Care connected care management platform, which became available in May 2020.
It is compatible with Abbott’s suite of neuromodulation technologies, including Infinity DBS System for patients with Parkinson’s disease or essential tremor, Proclaim XR SCS System for patients living with chronic pain, and Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.
The Patient Controller app with personalized access to therapy will be made available starting in the coming weeks, Abbott said.